A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0501. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Nogami, Naoyuki; Takigawa, Nagio; Hotta, Katsuyuki; Segawa, Yoshihiko; Kato, Yuka; Kozuki, Toshiyuki; Oze, Isao; Kishino, Daizo; Aoe, Keisuke; Ueoka, Hiroshi; Kuyama, Shoichi; Harita, Shingo; Okada, Toshiaki; Hosokawa, Shinobu; Inoue, Koji; Gemba, Kenichi; Shibayama, Takuo; Tabata, Masahiro; Takemoto, Mitsuhiro; Kanazawa, Susumu; Tanimoto, Mitsune; Kiura, Katsuyuki
• Is Part Of: Lung cancer. Volume 87:Issue 2(2015:Feb.)
• Page Start: 141
• Page End: 147
• Publication Date: 2015-02
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2014.11.001
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">A S-1-based chemo-radiation was effective and safe in stage III NSCLC.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">The median progression-free survival time was 9.3 months.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">The median survival time was 31.3 months.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Toxicities were generally mild except for febrile neutropenia and pneumonitis.</p> </list-item> </list> </p> </sec> </abstract>